By Annisa Sofia 
Researchers from the University of Oslo (UiO), Akershus University Hospital (Ahus), and a consortium of international collaborators have unveiled a groundbreaking expert review published in the prestigious journal Nature Aging. This landmark publication represents a significant convergence of over 25 leading scientists, encompassing seasoned clinicians and preeminent authorities in aging biology and metabolic science. The review meticulously synthesizes current knowledge and future directions, with a profound emphasis on nicotinamide adenine dinucleotide (NAD+), a vital molecule whose potential to support healthier aging and offer protection against neurodegenerative conditions like Alzheimer’s and Parkinson’s disease is increasingly recognized. This concerted global effort underscores a burgeoning scientific quest to harness the power of this fundamental biomolecule for human longevity and well-being.
The Pivotal Role of NAD+ in Cellular Health and Aging
NAD+, often described as a cell’s indispensable "fuel regulator," is a coenzyme that plays a central and multifaceted role in a myriad of essential cellular processes. It is critical for energy production, serving as a key player in the metabolic pathways that convert nutrients into usable energy for every cell in the body. Beyond its energetic functions, NAD+ is also indispensable for DNA repair mechanisms, acting as a substrate for enzymes like PARPs (poly(ADP-ribose) polymerases) that detect and mend DNA damage, a constant threat to genomic integrity. Furthermore, NAD+ is a vital component in cell signaling pathways, influencing processes such as gene expression, circadian rhythms, and cellular stress responses.
However, a significant and concerning biological reality is the natural decline of NAD+ levels as individuals age. This age-associated depletion is not merely an incidental consequence of growing older; it is increasingly implicated as a driving force behind many of the hallmarks of aging and the increased susceptibility to age-related diseases. The reduction in cellular NAD+ has been linked to a cascade of detrimental effects, including impaired mitochondrial function, leading to decreased energy production; compromised DNA repair, accelerating cellular senescence; and disruptions in cellular communication and homeostasis. Clinically, this decline has been correlated with a spectrum of age-related functional impairments, such as cognitive decline and memory deficits, a reduction in muscle strength and mass (sarcopenia), diminished cardiovascular function, and a heightened risk for developing chronic conditions like neurodegenerative disorders, metabolic syndromes, and certain cancers.
Dr. Jianying Zhang, one of the principal authors of the Nature Aging review, articulated the profound therapeutic potential of this molecular pathway. "Fine-tuning NAD+ metabolism holds promise for delaying age-related health decline as well as diseases such as premature aging diseases," she stated. "But to truly unlock its potential, we need to better understand the right doses, long-term safety, and interindividual variability in response to NAD+ augmentation strategies." This sentiment highlights the critical juncture at which scientific research finds itself: on the precipice of understanding a key aging mechanism, yet still requiring meticulous validation before widespread clinical application.
Early Promise and Emerging Challenges of NAD+ Supplementation
The comprehensive review delves into years of rigorous laboratory research and a growing body of clinical studies that have explored various strategies aimed at replenishing or boosting cellular NAD+ levels. A significant portion of these investigations focuses on the administration of NAD+ precursor molecules, which are vitamin-like compounds that the body can convert into NAD+. Among the most extensively studied precursors are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These compounds have garnered considerable attention due to their potential to effectively increase NAD+ levels within cells.
Early findings from some clinical trials involving NR and NMN have been encouraging, hinting at tangible benefits for human health. Reports from these preliminary studies have indicated improvements in various physiological markers, including enhanced cognitive function, particularly in areas of memory and executive function; improvements in physical performance, such as increased endurance and reduced fatigue; and positive shifts in metabolic health, including better insulin sensitivity and glucose regulation. These early successes have fueled optimism and driven further research into the therapeutic applications of NAD+ precursors.
However, the researchers are unequivocal in their cautionary stance, emphasizing that the current evidence, while promising, is not yet definitive. They stress the urgent need for larger-scale, longer-duration clinical trials involving diverse patient populations to rigorously confirm the efficacy and safety of these NAD+ augmentation strategies across a broader spectrum of age-related diseases. The nuances of how these precursors are metabolized, their bioavailability, potential off-target effects, and their long-term impact on health remain areas that require extensive scientific scrutiny. Furthermore, understanding how individual genetic makeup and existing health conditions might influence responses to these interventions is paramount.
A Growing Global Interest and the Intensifying Debate
The publication of this comprehensive review coincides with a period of escalating interest in NAD+ research and therapies, not only within the scientific community but also among the general public. Clinical trials are actively underway across the globe, including significant initiatives in Norway, dedicated to evaluating the therapeutic potential of NAD+ precursors like NR and NMN. These trials aim to systematically assess their impact on various health outcomes, from cognitive decline to cardiovascular health and metabolic disorders.
Simultaneously, these compounds have rapidly entered the burgeoning global dietary supplement market. This rapid commercialization has outpaced definitive scientific consensus, leading to a proliferation of products with varying formulations and claims. This has, in turn, ignited a vigorous debate within scientific and consumer circles concerning the optimal NAD+ boosting strategies, the efficacy of different precursor compounds, and critically, the extent to which findings from animal models can be reliably translated to human physiology and disease. The disconnect between preliminary research, market availability, and definitive clinical validation presents a complex landscape for both researchers and consumers.
Dr. Evandro Fei Fang-Stavem, the senior author of the paper and head of the Fang Lab at UiO and Ahus, underscored the critical need for expert guidance in this rapidly evolving field. "This is why we believe the timing is right to share an expert opinion," he remarked. "NAD+ is fundamental to life, yet there is still confusion and noise in the field about which supplements work best and how they should be used. Our article consolidates the evidence and provides a scientific roadmap to guide both ongoing research and future clinical use." This initiative aims to cut through the existing noise and provide a scientifically grounded foundation for future endeavors.
Professor Torbjørn Omland, Deputy Head of the Institute of Clinical Medicine at UiO and a co-author of the review, further elaborated on the importance of bridging the knowledge gap. "There is a knowledge gap on NAD+ and its clinical effects to basic researchers and clinicians, and this review paper provides the latest expert opinion to those who are interested in and are working in the field NAD+ research," he stated. "This review will also provide relevant information to many NAD+-based clinical trials across a wide spectrum of clinical conditions, including neurological and cardiovascular disease." The review’s intended audience includes not only those actively engaged in NAD+ research but also clinicians seeking to understand the latest scientific perspectives and their potential implications for patient care.
The Imperative for Enhanced Research and Global Synergy
The authors of the Nature Aging review are united in their emphasis on the indispensable need for further research and strengthened international collaboration. While the widespread investigation into NAD+-based supplements and therapies represents a significant scientific undertaking, they assert that more robust clinical testing and a concerted global effort are crucial. These steps are viewed as fundamental to transitioning promising early findings from the laboratory bench to safe, effective, and accessible treatments for the multifaceted challenges of aging and its associated diseases.
The implications of successfully leveraging NAD+ for healthier aging are far-reaching. Beyond mitigating the risk of debilitating neurodegenerative diseases, optimized NAD+ levels could contribute to improved cardiovascular health, enhanced metabolic function, preserved muscle mass and strength, and a general improvement in the quality of life during later years. This could translate into significant public health benefits, reducing the burden of age-related chronic diseases and enabling individuals to maintain their independence and vitality for longer.
The review also meticulously lists the Norwegian contributors, highlighting the strong domestic involvement in this global scientific endeavor. These include Sofie Lautrup (UiO and Ahus), Hilde Loge Nilsen (Oslo University Hospital – OUS), Leiv Otto Watne (Ahus and UiO), Geir Selbæk (UiO and Norwegian National Centre for Ageing and Health), Mathias Ziegler (University of Bergen – UiB), Ole-Bjørn Tysnes (UiB), and Charalampos Tzoulis (UiB). This broad participation from Norwegian institutions underscores the nation’s commitment to advancing research in aging and metabolism. Furthermore, the inclusion of international affiliations, such as the University of Copenhagen (Denmark), Chiba University (Japan), Harvard Medical School (USA), and the Buck Institute for Research on Aging (USA), emphasizes the truly global nature of this scientific undertaking and the necessity of shared knowledge and resources to tackle complex biological questions.
In conclusion, the publication of this expert review in Nature Aging marks a pivotal moment in the ongoing scientific exploration of NAD+. It serves as a vital synthesis of current knowledge, a clarion call for further rigorous research, and a beacon of hope for a future where interventions targeting NAD+ metabolism may play a significant role in promoting healthier aging and preventing age-related diseases. The collaborative spirit and the detailed roadmap provided by these leading scientists offer a promising path forward in unlocking the full therapeutic potential of this essential molecule.
